A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease
Filippatos, Gerasimos; Anker, Stefan D.; Boehm, Michael; Gheorghiade, Mihai; Kober, Lars; Krum, Henry; Maggioni, Aldo P.; Ponikowski, Piotr; Voors, Adriaan; Zannad, Faiez

Published in:
European Heart Journal

DOI:
10.1093/eurheartj/ehw132

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2016

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Download date: 23-12-2018
A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease

Gerasimos Filippatos1*, Stefan D. Anker2, Michael Böhm3, Mihai Gheorghiade4, Lars Køber5, Henry Krum6†, Aldo P. Maggioni7, Piotr Ponikowski8, Adriaan A. Voors9, Faiez Zannad10, So-Young Kim11, Christina Nowack11, Giovanni Palombo12, Peter Kolkhof13, Nina Kimmeskamp-Kirschbaum14, Alexander Pieper15, and Bertram Pitt16

1Department of Cardiology, National and Kapodistrian University of Athens, School of Medicine, Attikon University Hospital, Rimini 1, Haidari, Athens 12462, Greece; 2Department of Innovative Clinical Trials, University Medical Centre Gottingen, Gottingen, Germany; 3Universitätsklinikum des Saarlandes, Klinik für Innere Medizin III, Homburg, Germany; 4Feinberg School of Medicine, Northwestern University, Chicago, IL, USA; 5Heart Centre, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; 6Centre of Cardiovascular Research and Education in Therapeutics, Monash University, Melbourne, Australia; 7Research Centre of the Italian Association of Hospital Cardiologists, Florence, Italy; 8Medical University, Clinical Military Hospital, Wroclaw, Poland; 9University of Groningen, Groningen, Netherlands; 10Inserm, CHU Department of Cardiology, Université de Lorraine, Nancy, France; 11Global Clinical Development, Bayer Pharma AG, Leverkusen, Germany; 12Global Clinical Development, Bayer Plc, Newbury, UK; 13Heart Diseases Research, Global Drug Discovery, Bayer Pharma AG, Leverkusen, Germany; 14Global Research & Development Statistics, Bayer Pharma AG, Leverkusen, Germany; 15M.A.R.C.O. GmbH & Co. KG, Dusseldorf, Germany; and 16University of Michigan Medical School, Ann Arbor, MI, USA

Received 1 December 2015; revised 10 January 2016; accepted 21 February 2016; online publish-ahead-of-print 29 April 2016

See page 2115 for the editorial comment on this article (doi:10.1093/eurheartj/ehw155)

Aims
To evaluate oral doses of the non-steroidal mineralocorticoid receptor antagonist finerenone given for 90 days in patients with worsening heart failure and reduced ejection fraction and chronic kidney disease and/or diabetes mellitus.

Methods and results
Mineralocorticoid Receptor Tolerability Study-Heart Failure (ARTS-HF) was a randomized, double-blind, phase 2b multicentre study (ClinicalTrials.gov: NCT01807221). Of 1286 screened patients, 1066 were randomized. Patients received oral, once-daily finerenone (2.5, 5, 7.5, 10, or 15 mg, uptitrated to 5, 10, 15, 20, or 20 mg, respectively, on Day 30) or eplerenone (25 mg every other day, increased to 25 mg once daily on Day 30, and to 50 mg once daily on Day 60) for 90 days. The primary endpoint was the percentage of individuals with a decrease of >30% in plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) from baseline to Day 90. A key exploratory endpoint was a composite clinical endpoint of death from any cause, cardiovascular hospitalizations, or emergency presentation for worsening HF until Day 90. Mean age ranged from 69.2 to 72.5 years in different treatment groups (standard deviation 9.7–10.6 years). Decreases in NT-proBNP of >30% from baseline occurred in 37.2% of patients in the eplerenone group and 32.5, 38.8, and 34.2% in the 2.5 → 5, 5 → 10, 7.5 → 15, 10 → 20, and 15 → 20 mg finerenone groups, respectively (P = 0.02–0.88). Except for the 2.5 → 5 mg finerenone group, the composite clinical endpoint occurred numerically less frequently in finerenone-treated patients compared with eplerenone; this difference reached nominal statistical significance in the 5 → 20 mg group (hazard ratio 0.56, 95% confidence interval, CI, 0.35; 0.90; nominal P = 0.02), despite the fact that this phase 2 study was not designed to detect statistical significant differences. A potassium level increase to ≥5.6 mmol/L at any time point occurred in 4.3% of patients, with a balanced distribution among all treatment groups.
Conclusion

Finerenone was well tolerated and induced a 30% or greater decrease in NT-proBNP levels in a similar proportion of patients to eplerenone. The finding of reduced clinical events in the finerenone 10–20 mg group should be further explored in a large outcomes trial.

Keywords

Finerenone • Mineralocorticoid receptor antagonists • Worsening heart failure

Introduction

The steroidal mineralocorticoid receptor antagonists (MRAs) spironolactone and eplerenone reduce mortality and hospitalizations in patients with heart failure with reduced ejection fraction (HFrEF), and are recommended in European and US guidelines for symptomatic patients with HFrEF. While both spironolactone and eplerenone have been shown to be effective in patients with HFrEF, they may be underused or inconsistently prescribed in hospitalized patients with worsening heart failure (HF) because of a high risk of adverse events. Furthermore, patients with common comorbidities of HF such as diabetes mellitus (DM) or chronic kidney disease (CKD) are at particular risk of developing hyperkalemia, so may be less likely to receive currently available MRA therapy due to safety concerns. Thus, there is an unmet medical need in patients with worsening HF and impaired kidney function, which is not being met using currently available MRAs.

Finerenone (BAY 94-8862) is a novel non-steroidal MRA, with higher selectivity towards the mineralocorticoid receptor (MR) compared with spironolactone and stronger MR-binding affinity than eplerenone. This combination of potency and selectivity towards the MR and a balanced tissue distribution into heart and kidney compared with spironolactone or eplerenone could result in more pronounced cardiorenal protection, particularly in high-risk patients with impaired kidney function. The phase 2a mineralocorticoid Receptor Tolerability Study (ARTS) trial showed that in patients with HFrEF and mild CKD, finerenone (5.0–10.0 mg/d) had comparable efficacy with that of spironolactone (25 or 50 mg/d), with smaller increases in serum potassium level and smaller decreases in estimated glomerular filtration rate (eGFR). Further, the phase 2b ARTS-Diabetic Nephropathy trial confirmed the safety of finerenone in patients with diabetic kidney disease.

The ARTS-HF (Clinicaltrials.gov Identifier: NCT01807221) study was designed to compare the efficacy and safety of five different treatment regimens of once-daily oral doses of finerenone with eplerenone in patients with concomitant type 2 diabetes mellitus (T2DM) and/or CKD, who presented in emergency departments with worsening chronic HFrEF.

Methods

Study design

ARTS-HF has been described in detail elsewhere. Briefly, ARTS-HF was a randomized, double-blind, active-comparator-controlled, parallel-group, phase 2b, dose-finding study conducted at 173 centres in 25 countries. The study protocol was developed by the steering committee together with the sponsor (Bayer Pharma AG), and was approved by independent ethics committees and/or institutional review boards for all participating centres/countries before the study began. The study was carried out in accordance with Good Clinical Practice guidelines, the guiding principles of the Declaration of Helsinki, and applicable local laws and regulations. All participating patients gave written informed consent. Safety and tolerability were monitored by an independent Data Safety Monitoring Board and a central committee performed blinded adjudication of all hospitalizations and deaths.

Patients

Patients were recruited from June 2013 to August 2014 and were eligible for inclusion in the study if they were at least 18 years old and had worsening chronic HFrEF requiring hospitalization and treatment with intravenous diuretics. They also had to have T2DM and/or CKD (i.e. an eGFR of >30 mL/min/1.73 m² in patients with T2DM and 30–60 mL/min/1.73 m² in patients without T2DM), have been receiving treatment with evidence-based therapy for HF for at least the previous 3 months, and have a medical history of a left ventricular ejection fraction of 40% or less within the previous 12 months. Patients receiving treatment with spironolactone, eplerenone, renin inhibitors, or potassium-sparing diuretics at presentation had to be able to discontinue those treatments for 24 h before randomization (48 h for spironolactone) and for the duration of the study treatment period. Further details of the inclusion and exclusion criteria have been published previously.

Dosing, randomization, and masking

Randomization was carried out centrally by an interactive voice/web response system and participants, investigators, and the sponsor’s clinical team was blinded to treatment allocation. There were five preplanned finerenone treatment arms and one eplerenone treatment arm. The daily doses in the finerenone treatment arms (presented as ‘initial dose → uptitrated dose’; see ‘Procedures’ section below) were 2.5 → 5, 5 → 10, 7.5 → 15, 10 → 20, and 15 → 20 mg. The initial dose in the eplerenone treatment arm was 25 mg every second day; this could be increased to 25 mg once daily and then to 50 mg once daily if both uptitration steps were performed. Uptitrination of both study drugs and in all dose groups was performed if serum potassium levels remained ≤5.0 mmol/L. Patients were initially randomized 1:1:1 during the 7 days following hospital presentation to 1 of the 2 lowest preplanned finerenone doses (2.5 → 5 or 5 → 10 mg once daily) or eplerenone. The Data Safety Monitoring Board assessed safety and tolerability after randomization of ~300 patients in January 2014 and decided that the three remaining preplanned finerenone treatment arms could be introduced into the study. The randomization scheme was adapted to achieve a final randomization ratio of 1:1.5 between each finerenone dose group and the eplerenone group.
Procedures
Finerenone or eplerenone was administered on top of standard therapy for HF. The planned treatment duration was 90 days, with an additional follow-up period after the cessation of study drug for 30 days. The titration protocol was the same in all treatment groups: if blood potassium concentration was 5.0 mmol/L or less, the initial dose of finerenone or eplerenone was uptitrated at the end of the acute/vulnerable phase (Day 30), and an additional uptitration (eplerenone) or sham up titration (finerenone) was performed at Day 60. Treatment with the study drug was stopped if the patient had a confirmed blood potassium concentration of 5.6 mmol/L or more.

Outcomes
The primary study objective was to investigate the efficacy (percentage of responders; i.e. the number of patients with a decrease in plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) level of >30% from baseline to Day 90) and safety of different oral doses of finerenone given once daily.

Further exploratory efficacy endpoints included: (i) a composite endpoint of death from any cause, cardiovascular hospitalization, or emergency presentation for worsening chronic HF until Day 90; (ii) change in efficacy biomarkers (B-type natriuretic peptide, NT-proBNP, galectin 3, and N-terminal pro-collagen III propeptide); (iii) change in scores on health-related quality-of-life (QoL) questionnaires (the Kansas City Cardiomyopathy Questionnaire (KCCQ) and the five-dimension European Quality of Life Questionnaire (EuroQoL)). Clinical endpoints have been adjudicated by the event committee.

Effects on the following safety parameters were assessed: (i) biomarkers of organ injury (troponin T and cystatin C); (ii) vital signs; (iii) laboratory parameters (including potassium and serum creatinine concentrations, and eGFR); (iv) incidence of adverse events including those of special interest (i.e. an increase in serum potassium concentration to at least 5.6 mmol/L leading to discontinuation or emergency presentation for worsening chronic HF after starting treatment with the study drug).

Statistical analysis
Analyses were performed in three data sets: the safety-analysis set, full-analysis set, and per-protocol set (see Supplementary material online, Appendix). The primary endpoint was assessed in the full-analysis set (with missing data imputed using the last observation carried forward (LOCF)): the highest NT-proBNP value from the premature discontinuation and follow-up measurements were used in such cases; a supportive analysis was performed in the per-protocol set and several sensitivity analyses on the imputation method (including on-treatment LOCF, observed case analysis, and random imputation) were performed in the full-analysis set. For the primary endpoint, each finerenone group was compared with the eplerenone group using separate Chi-squared tests with continuity correction. In both cases, a one-sided significance level of 5% was applied. For each contingency table, estimated and two-sided 90% CIs were provided for each treatment groups and treatment differences.

Patients who died prior to Day 90, or who permanently discontinued study drug (>5 consecutive days) after cardiovascular hospitalization or after emergency hospital presentation for worsening chronic HF, were considered nonresponders to avoid biasing the primary efficacy analysis towards treatment responders.

The composite mortality/morbidity endpoint, its individual components, and cardiovascular mortality were assessed using the life-table and Kaplan–Meier methods. Differences between the finerenone and eplerenone groups were assessed using the log-rank test. This is an exploratory study, i.e. no confirmatory testing on the primary efficacy variable or other variables was performed. Further details of the statistical methods have been reported elsewhere.

Results
Patients
The disposition of the patients throughout the study is shown in Figure 1. Baseline characteristics were broadly similar across the treatment groups (Table 1). Of the 1066 randomized patients, 72.8% completed the study and 9.4% withdrew consent (Figure 1; see Supplementary material online, Table S1); the majority was receiving recommended pharmacologic therapy for chronic HF. Mean age ranged from 69.2 to 72.5 years in different treatment groups (standard deviation 9.7–10.6 years). The median NT-proBNP concentration at baseline was highest in the eplerenone group (5331 [range 148–47 774] pg/mL) and lowest in the finerenone 15 → 20 mg dose group (3750 [range 144–45 375] pg/mL). The median BNP concentration at baseline was highest in the finerenone 2.5 → 5 (715 pg/mL) and lowest in the finerenone 5 → 10 mg dose group (559 pg/mL).

Dosing
Maximum doses were reached in 77.3% of patients in the finerenone 2.5 → 5 mg group, 79.1% of the 5 → 10 mg group, 81.4% of the 7.5 → 15 mg group, 77.5% of the 10–20 mg group, and 73.6% of the 15 → 20 mg group. In the eplerenone group, 64.3% of patients reached the 50 mg daily dose. The average daily dose of eplerenone was 38.6 mg.

Efficacy
Primary efficacy endpoint
The proportion of patients who had an NT-proBNP level decrease of >30% at Day 90 compared with baseline was similar in the finerenone groups and the eplerenone group in the full-analysis set (Figure 2) and the per-protocol set (see Supplementary material online, Figure S1). The proportions of patients who had an NT-proBNP level decrease of >30% at Day 30 and at Day 60 compared with baseline were also not statistically different across the groups (see Supplementary material online, Figure S2). Sensitivity analyses on the imputation method indicated no relevant effect on the results by the imputation method (see Supplementary material online, Table S2).

Summary statistics for the NT-proBNP concentration ratio Day 90: baseline was similar between the groups (see Supplementary material online, Table S3). A mixed-effect model with factors treatment group, comorbidities, MRA use at emergency presentation, region, atrial fibrillation, time, treatment*time, and baseline NT-proBNP value as covariates also showed no differences between the eplerenone group and the finerenone groups (see Supplementary material online, Table S4).

Further exploratory efficacy endpoints
The incidence of the composite endpoint at Day 90 was lower in all finerenone groups compared with the eplerenone group, except for the finerenone 2.5 → 5 mg group (Figure 3 and see Supplementary material online, Table S5). The incidence of the composite endpoint
in the 10→20 mg dose group was nominally improved vs. that in the eplerenone group (hazard ratio, HR: 0.56; 95% CI: 0.35, 0.90; \(P = 0.02\)). Similar findings for the 10→20 mg dose group vs. eplerenone were observed for the individual components of death from any cause \([HR: 0.13 (95\% CI: 0.02, 1.07)]\), cardiovascular hospitalization \([HR: 0.56 (95\% CI: 0.34, 0.93)]\) and emergency presentation to hospital for worsening chronic HF \([HR: 0.58 (95\% CI: 0.33, 1.02)]\); see Supplementary material online, Table S5. The HRs were adjusted for log-transformed baseline NT-proBNP in a post hoc analysis, leading to only slightly higher values (see Supplementary material online, Table S6).

The changes in concentrations of galectin 3 and N-terminal pro-collagen III peptide from baseline to Day 90 were small. Mean scores on the KCCQ and the EuroQol Questionnaire improved at Day 90 compared with baseline in all treatment groups (see Supplementary material online, Table S7).

### Safety

All doses of finerenone had a similar safety profile to that of eplerenone. Incidences of treatment-emergent adverse events were similar between the eplerenone group and all finerenone dose groups (Table 2). Hyperkalaemia (serum potassium concentration \(\geq 5.6\) mmol/L) at any time post baseline was observed in 44 patients \((4.3\%)\), with a balanced distribution among the finerenone dose groups and the eplerenone group. Five patients \((1/212 (0.5\%))\) in the eplerenone group, and 1/164 (0.6%) and 3/160 (1.9%) in the
A randomized controlled study of finerenone vs. eplerenone

Baseline to Day 90 in all treatment groups. The size of the decrease was similar in the eplerenone group and the finerenone 5 → 10 mg, 7.5 → 15 and 10 → 20 mg dose groups. No clear dose relationship was observed in the finerenone groups (see Supplementary material online, Table S8).

Mean eGFR (as measured using the modification of diet in renal disease equation) increased slightly from baseline to Day 90 in the two lowest finerenone groups and decreased in the other groups (see Supplementary material online, Table S9). The proportion of

| Table 1 Patient demographics and clinical characteristics (safety-analysis set) |
|---------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Parameter                      | Eplerenone      | Finerenone 2.5 → 5 mg | Finerenone 5 → 10 mg | Finerenone 7.5 → 15 mg | Finerenone 10 → 20 mg | Finerenone 15 → 20 mg | Total |
| Mean age (SD) (years)          | 72.4 (9.9)      | 72.5 (9.7)      | 71.8 (10.6) | 69.3 (9.8) | 71.3 (10.2) | 69.2 (10.2) | 71.2 (10.1)      |
| Male sex, n (%)                | 170 (76.9)      | 135 (78.5)      | 126 (77.3) | 124 (74.3) | 128 (75.7) | 132 (81.0) | 816 (77.3)       |
| Region, n (%)                  |                 |                 |               |               |               |               |                 |
| Europe                         | 169 (76.5)      | 130 (75.6)      | 128 (78.5) | 131 (78.4) | 133 (78.7) | 132 (81.0) | 823 (78.0)       |
| North America                  | 14 (6.3)        | 9 (5.2)         | 8 (4.9)     | 15 (9.0)    | 13 (7.7)    | 10 (6.1)     | 69 (6.5)         |
| Asia                           | 7 (3.2)         | 7 (4.1)         | 4 (2.5)     | 5 (3.0)     | 7 (4.1)     | 7 (4.3)     | 37 (3.5)         |
| Other                          | 31 (14.0)       | 26 (15.1)       | 23 (14.1)   | 16 (9.6)    | 16 (9.5)    | 14 (8.6)    | 126 (11.9)       |
| New York Heart Association functional class before worsening, n (%) |               |                 |               |               |               |               |                 |
| II                             | 84 (38.0)       | 65 (37.8)       | 49 (30.1)   | 71 (42.5)   | 79 (46.7)   | 62 (38.0)   | 410 (38.9)       |
| III                            | 121 (54.8)      | 92 (53.5)       | 98 (60.1)   | 89 (53.3)   | 80 (47.3)   | 89 (54.6)   | 569 (53.9)       |
| IV                             | 16 (7.2)        | 15 (8.7)        | 16 (9.8)    | 7 (4.2)     | 10 (5.9)    | 12 (7.4)    | 76 (7.2)         |
| Risk factors, (%)              |                 |                 |               |               |               |               |                 |
| Type 2 diabetes mellitus (without CKD) | 55 (24.9)     | 39 (22.7)       | 36 (22.1)   | 49 (29.3)   | 48 (28.4)   | 53 (32.5)   | 280 (26.5)       |
| Type 2 diabetes mellitus with CKD | 84 (38.0)      | 68 (39.5)       | 71 (43.6)   | 59 (35.3)   | 60 (35.5)   | 56 (34.4)   | 398 (37.7)       |
| Chronic kidney disease (without T2DM) | 82 (37.1)     | 63 (36.6)       | 55 (33.7)   | 57 (34.1)   | 61 (36.1)   | 52 (31.9)   | 370 (35.1)       |
| Ischaemic heart disease        | 147 (66.5)      | 114 (66.3)      | 109 (66.9)  | 111 (66.5)  | 104 (61.5)  | 94 (57.7)   | 679 (64.4)       |
| Arterial hypertension          | 158 (71.5)      | 127 (73.8)      | 121 (74.2)  | 121 (72.5)  | 127 (75.1)  | 121 (74.2)  | 775 (73.5)       |
| Atrial fibrillation, ECG at baseline | 107 (48.4)    | 64 (37.2)       | 70 (42.9)   | 61 (36.5)   | 68 (40.2)   | 62 (38.0)   | 432 (40.9)       |
| Heart failure medications, n (%) |               |                 |               |               |               |               |                 |
| Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker at baseline | 173 (78.3)     | 131 (76.2)      | 129 (79.1)  | 130 (77.8)  | 127 (75.1)  | 134 (82.2)  | 824 (78.1)       |
| β-Blocker at baseline          | 189 (85.5)      | 137 (79.7)      | 141 (86.5)  | 146 (87.4)  | 148 (87.6)  | 146 (89.6)  | 907 (86.0)       |
| Mineralocorticoid receptor antagonist at index emergency presentation | 92 (41.6)      | 72 (41.9)       | 73 (44.8)   | 74 (44.3)   | 75 (44.4)   | 69 (42.3)   | 455 (43.1)       |
| Median N-terminal pro-B-type natriuretic peptide concentration (pg/mL) | 5331           | 5000            | 4386         | 4085         | 4543         | 3750          | 4517             |
| Median B-type natriuretic peptide concentration, (pg/mL) | 645            | 715             | 559          | 572          | 646          | 570           | 625              |
| Mean potassium concentration (SD), (mmol/L) | 4.1 (0.5)      | 4.1 (0.5)       | 4.2 (0.5)   | 4.2 (0.4)   | 4.1 (0.5)   | 4.2 (0.5)   | 4.1 (0.5)       |
| Mean eGFR* (SD), (mL/min 1.73 m²) | 52 (18)        | 52 (16)         | 52 (16)     | 55 (20)     | 53 (17)     | 55 (19)     | 53 (18)         |
| Mean eGFR*, ≤ 60 mL/min 1.73 m², n (%) | 159 (72)       | 120 (70)        | 127 (78)    | 116 (69)    | 120 (71)    | 110 (67)    | 752 (71)        |
| Mean creatinine concentration (SD), (mg/dL) | 1.5 (0.4)      | 1.5 (0.4)       | 1.5 (0.4)   | 1.4 (0.4)   | 1.4 (0.4)   | 1.4 (0.4)   | 1.4 (0.4)       |
| Mean urinary albumin:creatinine ratio (SD), (g/kg) | 52 (5)         | 50 (5)          | 43 (5)      | 41 (5)      | 41 (5)      | 39 (5)       | 45 (5)          |
| Mean urinary albuminuria, n (%) | 124 (56.1)     | 97 (56.3)       | 80 (49.1)   | 85 (50.9)   | 95 (56.2)   | 77 (47.3)   | 558 (52.9)      |
| Mean systolic blood pressure (SD), (mmHg) | 121 (19)       | 119 (16)        | 118 (14)    | 119 (17)    | 116 (17)    | 117 (17)    | 119 (17)        |
| Mean heart rate (SD), (beats/min) | 75 (14)        | 73 (13)         | 73 (13)     | 74 (12)     | 74 (12)     | 74 (13)     | 74 (13)         |
| Mean ejection fraction (SD) | 29.8 (7.5)     | 29.3 (7.8)      | 28.7 (7.4)  | 28.5 (7.4)  | 29.0 (8.0)  | 29.0 (7.5)  | 29.1 (7.6)       |

SD, standard deviation.
*Estimated glomerular filtration rate was calculated using the modification of diet in renal disease equation.
Figure 2  Proportion of patients with a decrease of >30% in plasma N-terminal pro-B-type natriuretic peptide concentration from baseline at Day 90 (full-analysis set). Patients who died prior to Day 90 or who experienced permanent (≥5 consecutive days) withdrawal of study drug after a cardiovascular hospitalization or emergency presentation for worsening chronic heart failure were counted as nonresponders for the primary efficacy analysis.

Figure 3  Mortality/morbidity outcomes in patients with worsening chronic heart failure with reduced ejection fraction receiving eplerenone or different doses of finerenone. Cumulative event rates of the composite endpoint of death from any cause, cardiovascular hospitalization, or emergency presentation for worsening chronic heart failure in the full-analysis set.
Table 2  Incidence of treatment-emergent adverse events and hyperkalaemia in patients with worsening chronic heart failure with reduced ejection fraction receiving eplerenone or finerenone (safety-analysis set)

<table>
<thead>
<tr>
<th>Adverse event parameter</th>
<th>Incidence, n (%)</th>
<th>Eplerenone n = 221</th>
<th>Finerenone 2.5—5 mg n = 172</th>
<th>Finerenone 5—10 mg n = 163</th>
<th>Finerenone 7.5—15 mg n = 167</th>
<th>Finerenone 10—20 mg n = 169</th>
<th>Finerenone 15—20 mg n = 163</th>
<th>Total N = 1055</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any treatment-emergent adverse event</td>
<td>170 (76.9)</td>
<td>132 (76.7)</td>
<td>124 (76.1)</td>
<td>105 (62.9)</td>
<td>120 (71.0)</td>
<td>128 (78.5)</td>
<td>779 (73.8)</td>
<td></td>
</tr>
<tr>
<td>Any treatment-emergent serious adverse event</td>
<td>77 (34.8)</td>
<td>72 (41.9)</td>
<td>47 (28.8)</td>
<td>52 (31.1)</td>
<td>46 (27.2)</td>
<td>57 (35.0)</td>
<td>351 (33.3)</td>
<td></td>
</tr>
<tr>
<td>Discontinuation due to treatment-emergent adverse event</td>
<td>32 (14.5)</td>
<td>21 (12.2)</td>
<td>25 (15.3)</td>
<td>25 (15.0)</td>
<td>17 (10.1)</td>
<td>21 (12.9)</td>
<td>141 (13.4)</td>
<td></td>
</tr>
<tr>
<td>Study drug-related treatment-emergent adverse event</td>
<td>39 (17.6)</td>
<td>34 (19.8)</td>
<td>28 (17.2)</td>
<td>32 (19.2)</td>
<td>27 (16.0)</td>
<td>29 (17.8)</td>
<td>189 (17.9)</td>
<td></td>
</tr>
<tr>
<td>Study drug-related treatment-emergent serious adverse event</td>
<td>9 (4.1)</td>
<td>10 (5.8)</td>
<td>7 (4.3)</td>
<td>11 (6.6)</td>
<td>6 (3.6)</td>
<td>11 (6.7)</td>
<td>54 (5.1)</td>
<td></td>
</tr>
<tr>
<td>Treatment-emergent adverse events of special interest</td>
<td>44 (19.9)</td>
<td>38 (22.1)</td>
<td>28 (17.2)</td>
<td>34 (20.4)</td>
<td>25 (14.8)</td>
<td>35 (21.5)</td>
<td>204 (19.3)</td>
<td></td>
</tr>
<tr>
<td>Hyperkalaemia from baseline to Day 30*</td>
<td>1/178 (0.6)</td>
<td>1/136 (0.7)</td>
<td>2/138 (1.4)</td>
<td>0/142 (0.0)</td>
<td>2/144 (1.4)</td>
<td>1/137 (0.7)</td>
<td>7/875 (0.8)</td>
<td></td>
</tr>
<tr>
<td>Potassium concentration ≥ 5.6 mmol/L</td>
<td>0/178 (0.0)</td>
<td>0/136 (0.0)</td>
<td>0/138 (0.0)</td>
<td>0/142 (0.0)</td>
<td>0/144 (0.0)</td>
<td>1/137 (0.7)</td>
<td>1/875 (0.1)</td>
<td></td>
</tr>
<tr>
<td>Potassium concentration &gt; 6.0 mmol/L</td>
<td>10/212 (4.7)</td>
<td>6/165 (3.6)</td>
<td>6/157 (3.8)</td>
<td>6/164 (3.7)</td>
<td>6/165 (3.6)</td>
<td>10/160 (6.3)</td>
<td>44/1023 (4.3)</td>
<td></td>
</tr>
<tr>
<td>Hyperkalaemia at any time post baseline*</td>
<td>1/212 (0.5)</td>
<td>0/165 (0.0)</td>
<td>0/157 (0.0)</td>
<td>1/164 (0.6)</td>
<td>0/165 (0.0)</td>
<td>3/160 (1.9)</td>
<td>5/1023 (0.5)</td>
<td></td>
</tr>
<tr>
<td>Emergency presentation for worsening chronic heart failure</td>
<td>40 (18.1)</td>
<td>33 (19.2)</td>
<td>23 (14.1)</td>
<td>26 (15.6)</td>
<td>19 (11.2)</td>
<td>30 (18.4)</td>
<td>171 (16.2)</td>
<td></td>
</tr>
</tbody>
</table>

*Incidence of hyperkalaemia is presented as n/n with available data (%).

Discussion

Mineralocorticoid receptor antagonists have not been systematically studied in patients with worsening HFrEF who require emergency admission to hospital. However, evidence from the use of MRAs in other patient groups and the intense neurohormonal activation in patients with worsening HF suggests that the MR may be an important therapeutic target in this population with very high morbidity and mortality despite current therapy.

ARTS-HF is the first clinical trial to compare the novel nonsteroidal MRA finerenone with eplerenone in this population with a high unmet medical need i.e. patients with worsening HFrEF requiring emergency treatment and who also have DM and/or CKD. This period of acute worsening is a crucial time for treatment of patients with HFrEF because mortality and morbidity are known to increase following emergency presentation. In this high-risk population, finerenone was well tolerated with a safety profile comparable with that of eplerenone. The proportion of patients who had an NT-proBNP level decrease of ≥30% from baseline to Day 90 was similar in the finerenone and eplerenone groups. Although the absolute decrease in NT-proBNP was highest in the eplerenone group, this may be due to the fact that this group had the highest NT-proBNP levels at baseline. However, the incidences of the exploratory composite endpoint of death from any cause, cardiovascular hospitalization, or emergency presentation for worsening HF at Day 90 were lower in most finerenone groups compared with eplerenone. Changes in other efficacy biomarkers and QoL questionnaires were similar between finerenone and eplerenone groups.

Eplerenone was chosen as the active comparator for ARTS-HF because it was considered to be more suitable than spironolactone for patients with DM (owing to the metabolic effects of...
spironolactone or CKD (owing to the safety profile of spironolactone in patients with moderate CKD). Given that >70% of the study population had an eGFR ≤ 60 mL/min/1.73 m² at baseline, the starting dose of eplerenone chosen (25 mg every second day) is in line with the recommended starting dose of eplerenone in stable patients with HFpEF and CKD.

Overall, patients in the finerenone 10 → 20 mg dose group had the greatest reduction in the composite outcome including death from any cause, cardiovascular hospitalization, or emergency presentation to hospital, compared with patients in the eplerenone group (HR: 0.56; 95% CI: 0.35, 0.90).

Together, these observations suggest a better outcome in the finerenone 10 → 20 mg group compared with the other finerenone groups and the eplerenone group, combined with a safety profile that is comparable with that in the other groups. There are mechanisms that may explain the decrease in the clinical composite endpoint in the finerenone group. Finerenone has a unique pharmacodynamic profile, which is considered to be the consequence of different physicochemical properties in comparison with steroidal MRAs. Physicochemical drug properties have a strong impact on plasma protein binding, vascular transport, and tissue penetration and distribution. Moreover, finerenone has a different mode of mineralocorticoid receptor inactivation compared with steroidal MRAs, which may lead to a pronounced suppression of downstream gene expression leading to hypertrophy and, thus, improved organ protection. However, the reason why outcomes seem to be improved, particularly in the finerenone 10 → 20 mg compared with the 15 → 20 mg group, is unclear at this stage.

Both finerenone and eplerenone were well tolerated overall, with a similar rate of adverse events across all study groups and a low incidence of renal events leading to hospitalization. Overall, 4.3% of patients experienced serum potassium concentration ≥ 5.6 mmol/L. A potassium concentration > 6.0 mmol/L was observed in only five patients (0.5%), with no such elevations observed in the finerenone 2.5 → 5 mg, 5 → 10 and 10 → 20 mg dose groups.

Although MRA use has been limited by safety concerns in patients with HF and concomitant diabetes or renal impairment, previous studies have shown that their clinical benefits are maintained in these patient groups. In RALES, spironolactone efficacy was maintained in patients with an eGFR < 60 mL/min/1.73 m². In EMPHASIS-HF, the cumulative rate of the primary endpoint (HF hospitalization or cardiovascular mortality) remained significantly reduced in the eplerenone group compared with the placebo group in the subset of patients with DM or renal dysfunction. In EPHESUS, a history of DM and an eGFR ≤ 60 mL/min/1.73 m² were each identified as risk factors for developing a serum potassium concentration ≥ 6.0 mEq/L, but did not alter the cardiovascular benefit of eplerenone.

Introduction of a novel neurohormonal blocking agent into clinical practice in patients with HFpEF already on standard therapy may be challenging, particularly when the new agent should replace a cornerstone drug of this regimen. In the present study, 43% of patients were already on MRA therapy with spironolactone or eplerenone at baseline. In those patients, spironolactone and eplerenone were discontinued 48 or 24 h before randomization, respectively. This strategy was well tolerated and, thus, ARTS-HF provides some practical insights into how these agents should be introduced.
in the clinical practice. Pending the results of further clinical studies, it is possible that this non-steroidal MRA will provide an alternative therapy option for patients with HF in particular in those who are at high risk of developing hyperkalaemia.

**Study limitations**

The primary efficacy endpoint in ARTS-HF was based on a surrogate marker of efficacy: the proportion of patients who experienced a > 30% reduction in NT-proBNP levels. Prospective studies showed that decreases in plasma NT-proBNP concentrations of 30% or more correlate with improved prognosis 12–15 but also changes in natriuretic peptides by several drugs were not related to improved outcome in clinical trials. 16–21 N-terminal pro-B-type natriuretic peptide levels may be increased in patients with atrial fibrillation and HF compared with those without atrial fibrillation. A factor to account for atrial fibrillation was included when performing an analysis of covariance for the absolute change in NT-proBNP levels. There were differences in NT-proBNP at baseline between the groups, which were also considered within the ANCOVA for absolute change in NT-proBNP levels by adjusting for logarithmized baseline NT-proBNP. 10

In addition, the composite of death from any cause, cardiovascular hospitalizations, or emergency presentations for worsening HF was only a secondary endpoint and the observed event rate was low. Therefore, these findings need to be confirmed by subsequent studies with higher event rates, and longer treatment duration and follow-up, in order to draw firm conclusions.

**Conclusions**

ARTS-HF is the first clinical trial to compare the novel nonsteroidal MRA finerenone with eplerenone in a unique and vulnerable patient population. In patients with worsening HFrEF requiring hospitalization and who also had DM and/or CKD, finerenone reduced levels of NT-proBNP to a similar extent to that of eplerenone with a good safety profile. The present study provides the grounds for the further evaluation of this novel non-steroidal MRA in the setting of a phase 3 study and also indicates that 10 → 20 mg is the most suitable dosage scheme to be tested.

**Authors’ contributions**

A.P.: performed statistical analysis; S.-Y.K., C.N.: handled funding and supervision; G.F., B.P.: handled funding and supervision; Steering Committee: acquired the data, conceived and designed the research; G.F., S.-Y.K., C.N., B.P.: drafted the manuscript; all other authors: made critical revision of the manuscript for key intellectual content.

**Supplementary material**

Supplementary material is available at European Heart Journal online.

**Acknowledgements**

This study was funded by Bayer Pharma AG. Charlotte Cookson DPhil of Oxford PharmaGenesis™ provided medical writing support funded by Bayer Pharma AG.

**Funding**

The study was designed by the Steering Committee in collaboration with the sponsor (Bayer Pharma AG). The sponsor also had a role in data collection and performed the statistical analysis. The corresponding author had responsibility for the manuscript and decision to submit for publication. All authors participated in manuscript revision and vouch for the accuracy and completeness of the data reported. Funding to pay the Open Access publication charges for this article was provided by the Bayer Pharma AG.

**Conflict of interest:** S.D.A., M.B., M.G., L.K., H.K., A.P.M., B.P., P.P., A.A.V., F.Z., and G.F. were members of the Steering Committee for ARTS-HF. S.D.A. has received consulting fees from Bayer Pharma AG. M.B. has received research support and speaker honoraria from Bayer Pharma AG, Boehringer Ingelheim GmbH, Medtronic, Inc., Pfizer Inc., Servier, and St Jude Medical, Inc. G.F. is a member of the Steering Committee of trials sponsored by Bayer Pharma AG, Cardiorenis, the European Commission, Medtronic, Novartis, and Vifor Pharma. M.G. has received consulting fees for Bayer Pharma AG, Cardiocl, J&J, Novartis, Otsuka Pharmaceutical, and Takeda. H.K. has received research grants and consulting fees from Bayer Pharma AG. L.K. has been a speaker for Bayer Pharma AG, Novartis, and Servier. N.K.K., S.-Y.K., G.P., and C.N. are employees of Bayer Pharma AG. A.P.M. is a member of the Steering Committee of trials sponsored by Bayer Pharma AG, Novartis, Abbott Vascular, and Cardiorenis. A.P. provided clinical trial support funded by Bayer Pharma AG. B.P. has received consulting fees for Bayer Pharma AG, Eli Lilly and Pfizer Inc.; has stock options in Relypsa Inc.; and has a patent pending on site-specific delivery of eplerenone to the myocardium. P.P. received speaker honoraria and advisory-board-member honoraria from Bayer Pharma AG. A.A.V. has received consulting and speaker fees and/or research grants from Agen, Bayer Pharma AG, Cardio3Biosciences, Celladon, Novartis, Merck/MSD, Servier, Takeda, Trevena, and Vifor Pharma and is supported by research grants from the European Commission (FP7-242209-BIOSTAT-CHF) and the Dutch Heart Foundation. F.Z. is a consultant or has received honoraria from Air Liquide, Bayer Pharma AG, Biomerieux, Biotronik, Boston Scientific, Janssen, Novartis, Pfizer, Resmed, Servier, St Jude, and Takeda; has received speaker fees from Mitsubishi; has stocks in Cardiorenan Diagnostics; and has received grants or research support from BG Medicine and Roche Diagnostics. B.P. has received consulting fees from Bayer Pharma AG, Pfizer, Astra Zeneca, Relyspa, Stealth peptides, Forest Laboratories, scPharmaceuticals, Sarfex; has stock options in Relypsa, scPharmaceuticals; and has a patent pending on the site-specific delivery of eplerenone to the myocardium.

**References**


